Characteristic | Value Values are median (range) or No. of patients/tumors (%). |
---|---|
Age, year | 64 (22 |
Men | 50 (77) |
Primary cancer | |
Lung | 49 (70) |
Colorectal | 10 (14) |
Other (breast, gastric, melanoma, germ cell, RCC) | 11 (16) |
Treatment indication | |
Primary lung (medically inoperable T1–T2) | 12 (17) |
Relapse (primary lung and oligometastatic) | 24 (34) |
Oligometastatic | 34 (49) |
Previous radiation to chest | 20 (29) |
Tumor location | |
≤ 1 cm from tracheobronchial tree | 24 (34) |
> 1 cm but ≤ 2 cm from tracheobronchial tree | 12 (17) |
Lesions intersecting mediastinum | 22 (31) |
≤ 1 cm from thoracic aorta | 12 (17) |
Left laterality | 37 (53) |
Lesion size (PTV), cc | 33.4 (7.3–461.5) |
Total dose, Gy | 55 (30–60) |
Dose per fraction, Gy | 9.75 (4–18) |
Fractions | 5 (3–10) |
BED10, Gy | 110 (48–151.2) |
BED10 | |
< 100 Gy | 16 (23) |
≥ 100 Gy | 54 (77) |
BED3, Gy | 228 (90–378) |
Treatment time, days | 10 (5–19) |
Treatment time | |
< 10 days | 30 (43) |
≥ 10 days | 40 (57) |
Treatment on consecutive days | 6 (9) |
Characteristic | Value Values are No. patients/tumors (%) or No. patients unless otherwise stated. |
---|---|
Response on 3-month PET/CT after SABR | |
Complete response | 43 (61) |
Partial response | 19 (27) |
Progression | 2 (3) |
Unknown (patient died before 3 months or imaging not performed) | 6 (9) |
Locoregional control | |
2-year | 84% |
5-year | 70% |
Median | Not reached |
Overall survival | |
2-year | 52% |
5-year | 28% |
Median | 28 months |
2-Year toxicity-free survival | 81% |
All Toxicities (grade 2 or higher) | 17 (26.2%) |
RT-induced pneumonitis | 9 (13.8%) |
Brachial and recurrent laryngeal nerve injury | 3 (4.6%) |
Esophagitis | 2 (3%) |
Tracheal perforation | 1 (1.5%) |
Fatal hemoptysis | 1 (1.5%) |
Possible RT-related death | 1 (1.5%) |
Toxicity, grade 5 (fatal) | 5 (7.7%) |
RT-induced pneumonitis | 2 (3%) |
Tracheal perforation | 1 (1.5%) |
Fatal hemoptysis | 1 (1.5%) |
Possible RT-related death | 1 (1.5%) |